Question explored with the scientific record
Does breast mammography screening save lives?
The short version: for women 50 to 69, screening probably prevents some breast cancer deaths, but the effect is smaller than advertised, it does not extend life overall, and it comes with real overdiagnosis and false alarms.
The best evidence here is the randomized trials, and they disagree with each other. A pooled look at five Swedish trials found about a 24% drop in breast cancer deaths among women invited to screening, with the biggest effect in women 50 to 69 [1]. A 2016 meta-analysis for the US task force found a real benefit in women 50 to 69 but nothing statistically solid for women 39 to 49 or 70 to 74 [3]. Meanwhile a Norwegian population study found no significant mortality reduction once it compared eligible to ineligible women, suggesting better treatment and awareness explain the fall [2]. The Canadian trial found no benefit in women 40 to 59 [6].
| Group | Breast cancer death reduction | Source |
|---|---|---|
| Swedish trials, invited women | 24% | [1] |
| Meta-analysis, ages 50-59 | 14% | [3] |
| Meta-analysis, ages 60-69 | 33% | [3] |
| Meta-analysis, ages 39-49 | not significant | [3] |
| Norway, eligible vs ineligible | no significant reduction | [2] |
Here is the part the brochures leave out. None of the randomized trials showed any effect on all-cause mortality, and with 660,000 women enrolled a 2% drop should have been detectable [5]. Screening also overdiagnoses: one estimate puts it at 31%, or 15 women per 1,000 invited to biennial screening for 20 years from age 50 [5]. For every 1,000 women invited, about 200 get a false positive and 30 get a biopsy for nothing [5]. The Dutch program found advanced cancer incidence did not fall over time, and at least 65% of advanced cancers could not have been caught earlier [4].
My call: for women 50 to 69, screening probably prevents a modest number of breast cancer deaths, but it does not clearly extend overall life, and the overdiagnosis and false-alarm costs are real and understated. For women 40 to 49 the mortality evidence is weak and the balance is closer to a wash. Confidence: moderate for ages 50 to 69, low for ages 40 to 49.
Sources used 6
-
Breast cancer screening with mammography: overview of Swedish randomised trials
This study provides an overview of five randomized trials in Sweden, demonstrating a 24% significant reduction in breast cancer mortality among women invited to mammography screening compared to those not invited, based on a cohort of 282,777 women followed for 5-13 years.
DOI: 10.1016/0140-6736(93)91067-v -
Effect of organized mammography screening on breast cancer mortality: A population‐based cohort study in Norway
This population-based cohort study in Norway found no significant reduction in breast cancer mortality among women eligible for organized mammography screening compared to ineligible women, suggesting that improvements in breast cancer treatment and awareness may account for mor…
DOI: 10.1002/ijc.31832 -
Effectiveness of Breast Cancer Screening: Systematic Review and Meta-analysis to Update the 2009 U.S. Preventive Services Task Force Recommendation
This systematic review and meta-analysis evaluates the effectiveness of mammography screening in reducing breast cancer mortality among average-risk women, updating the 2009 U.S. Preventive Services Task Force recommendations.
DOI: 10.7326/M15-0969 -
Trends in incidence and detection of advanced breast cancer at biennial screening mammography in The Netherlands: a population based study
In the Dutch biennial mammography screening programme, advanced breast cancer incidence did not decrease over time and at least 65% of advanced cancers could not have been diagnosed earlier, questioning screening's effect on advanced disease.
DOI: 10.1186/bcr3091 -
Benefits and harms of mammography screening
Mammography screening reduces breast cancer mortality by 15-25% in trials and 13-17% in observational meta-analyses, but causes overdiagnosis, false positives, and no all-cause mortality benefit; women should receive balanced absolute-risk information.
DOI: 10.1186/s13058-015-0525-z -
Controversies in the Use and Periodicity of Mammography as a Screening Method for Breast Cancer
This study critically examines the controversies surrounding the use and periodicity of mammography as a screening method for breast cancer, highlighting the lack of significant mortality reduction and the risks of overdiagnosis associated with screening practices.
DOI: 10.1055/s-0038-1648218